Sure, new indications are great. It potentially expands the pipeline and signals that the drug could be used for multiple applications. But in this current risk off environment I am absolutely not surprised it had no affect on the price as this is not company making news. Focus is on the trial and always has been.
I have no doubt the trial will commence at some stage and as another member said I also wouldn't be surprised if it was delayed due to current global circumstance. That's fine.
What I really want to know is what route they plan to take with regards to the $14m outstanding to get this trial to futility. This question has been lingering since the failed retail offer.
Then the other question for down the track is how long it will take to recruit patients and when the last patient is dosed so we can get an approximate timeline on when to expect futility results.
- Forums
- ASX - By Stock
- PER
- Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2
Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2, page-68
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $90.15M |
Open | High | Low | Value | Volume |
11.0¢ | 11.0¢ | 10.0¢ | $52.56K | 502.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 176914 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 217753 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 176914 | 0.100 |
1 | 50000 | 0.099 |
1 | 100000 | 0.098 |
1 | 30927 | 0.097 |
1 | 1373 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 217753 | 2 |
0.110 | 738750 | 8 |
0.115 | 1033419 | 5 |
0.120 | 178142 | 6 |
0.125 | 25000 | 1 |
Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |